Company Facts
Company Facts
Mission
Rainbow Holdings & Joint Ventures
Rainbow Holdings and Joint Ventures leverages our precision medicine platform, producing vertical human health businesses that
Determine risks of over 7000 human disorders that are caused by genetic abnormality
Prevent disease onset, with timely intervention, by assessing damages at the protein level
Provide personalized treatment
Deliver substantially-improved health outcome compared to traditional medical practices, resulted in quantifiable reductions in health care cost at institutional and national levels
Our products and services are supported by large-scale human genomics (whole genome sequencing with deep phenotyping), proteomics (measure 7000 proteins per person), our multi-omics diagnostic capabilities, and our proprietary biomarker-disease-treatment databases.
We provide platform-level deployments of proprietary diagnostics, knowledgebases, personalized clinical analysis and intervention, resulted in new prevention and treatment paradigms that substantially reduce health care cost at institutional and national scales.
Our current clinical programs include heart diseases, cancers, cardio-metabolic and neuro-degenerative disorders.
Rainbow Genomics Mission
Rainbow Genomics, one of the vertical businesses of Rainbow Holdings, is a clinical genetic applications company, focusing on applying a wide range of proven genomic and proteomic technologies, to enable physicians, patients and healthy individuals to understand genetic variations, leading to improved treatment and health care outcomes.
We are a pioneer in the commercialization of genomic- and protein-based, diagnostic and preventive health care solutions to individuals.
We are committed to providing clinically-validated and evidence-based, multi-genomics testing to Asian, Caucasian and mixed-race patients.
We specialize in providing whole genome, whole exome, transcriptome, long-read, methylation, small RNA, Sanger and single cell sequencing, pharmacogenomic, cancer, heart health, and genomic health tests, enabling individuals and their physicians to use genomic information for diagnosis, treatment and disease prevention.
Coupled with our multi-genomic technology and multi-bioinformatic-platform approach, we work hard to improve overall diagnostic yield to enable timely treatment for patients affected by rare diseases, developmental, neurological, prenatal, hereditary cancer and cardio conditions.
We also utilize proteomic, and metabolomic technologies to improve the determination of multiple types of health risks.
Company
Rainbow is a provider of genetic testing and protein-based risk assessment services.
Our market coverage includes pediatric and adult hereditary disorders (also known as rare diseases), pharmacogenomics, and common disease risk assessment with clinical utilities. We understand how to integrate clinical best practices with localized "product components" to address various market segments.
Asia-Pacific Market
We co-developed clinical applications with our institutional partners, and deploy credible clinical assessment products through highly-effective channels, to address both the domestic and medical tourism markets in Hong Kong, Japan, other Asian countries.
U.S. Market
We also provide “for research use” genetic analysis, discovery and confirmatory sequencing services in the U.S.
Our management and clinical advisory teams consist of genetics, health care, ethics and public policy experts with substantial research and clinical experience. We deliver clinical applications via multiple clinical platforms.
Our primary product -Exome Sequencing
Our primary product -Exome Sequencing
Our Primary Product Line - Clinical Whole Genome Sequencing Tests
Clinically-Actionable Reports
The human genome consists of 3 billion nucleotides or “letters” of DNA. Only a small fraction, about 1.5% of the genome, contains genes that encode proteins, which control various functions in the body. Much of what we know about genetic disorders are based on these genes, or what we collectively called the exome. An exome contains more than 20,000 genes.
The Rainbow Whole Genome Sequencing test analyzes 3 billion nucleotides, pushing diagnostic yields to a high level, meeting or exceeding those reported by leading U.S. and European medical institutions. We also deploy RNA sequencing, microarray, and long-read sequencing to detect and confirm highly-challenging mutations.
Rainbow also provides a range of low-cost Whole Exome Sequencing tests, analyzing over 20,000 genes, and providing clinical reports that are based on clear medical evidence.
We also deploy microarray and high-density DNA array genotyping, RNA sequencing, Sanger, methylation, single cell, and long-read sequencing to detect and confirm highly-challenging mutations.
Most direct-to-consumer tests provide hundreds or even thousands of genetic findings that lack clinical utilities. Unlike these "recreational genetic tests", the Rainbow whole genome sequencing tests provide clinically- actionable results related to disorders for which your physicians can manage, treat or prevent.
Proteomics
We are a pioneer in adopting 7000-protein analysis to better estimate lifetime and imminent risks of disease onsets. Current diagnostic programs include the combined use of genomics and proteomics for heart attack, lung cancer, diabetes and dementia risk assessment.
Precision Medicine
for
Asian, Mixed-Race and ethnic-minority Patients
Unlike many genetic tests using a small number of genes (1-200 genes in a fixed panel), Rainbow utilizes the entire genome or exome for analysis and clinical interpretation. Analyzing the entire genome reduces the risk of not including sufficient ethnic-specific genes. This is a concern because many of these gene panels were designed based on clinical studies using Caucasian patients in the U.S. and Europe. There is often insufficient evidence to confirm the clinical utilities of these genes for Asian, mixed-race and ethnic-minority patients. Whole genome sequencing test reduces this risk.
As new genetic variants are discovered, especially by Asian clinicians, and more variants of uncertain clinical significance (VUS) are reclassified as pathogenic or likely-pathogenic mutations, we can provide timely reports for previously-unresolved clinical cases.
Regulatory Compliance
Regulatory Compliance
Comply with U.S. Clinical Regulatory & Patient Privacy Standards
Our clinical interpretation follows the current ACMG (American College of Medical Genetics and Genomics) guidelines. The clinical partners also issue physician reports signed-off by their board-certified medical directors or clinical geneticists.
All Rainbow tests are performed at CAP (College of American Pathologists) accredited and CLIA (Clinical Laboratory Improvement Amendments) certified laboratories.
Patient data privacy – Rainbow follows the U.S. Health Insurance Portability and Accountability Act (HIPAA) privacy rules, established to protect the confidentiality of patients' individually identifiable health information.
Japanese Clinical Guidelines
Additional clinical interpretation provided by the Juntendo University Medical School is in compliance with Japan’s clinical testing guidelines
Our Operations
Operations
Our Operations
Operations
San Francisco
Rainbow Genomics maintains operations in the U.S. and Hong Kong.
Our English-speaking, Hong Kong-based project managers work closely with ordering physicians all over Asia to collect patient samples, manage testing process, and coordinate physician report delivery.
Our partner laboratories, U.S. and Japanese medical institutions support the entire clinical testing process.
Hong Kong
Our genetic counselors and physician specialists provide multilingual (English with Japanese, Mandarin or Cantonese) genetic counseling to our patients, and consultation to physicians in local communities.
